Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) was the target of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 6,270,000 shares, a decrease of 5.3% from the May 15th total of 6,620,000 shares. Based on an average daily volume of 691,800 shares, the short-interest ratio is presently 9.1 days.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on CLDX. Guggenheim increased their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Wolfe Research began coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $63.00.
Read Our Latest Analysis on CLDX
Insider Buying and Selling at Celldex Therapeutics
Institutional Trading of Celldex Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Celldex Therapeutics in the first quarter worth about $824,000. Artal Group S.A. purchased a new position in shares of Celldex Therapeutics during the first quarter valued at approximately $10,618,000. California State Teachers Retirement System lifted its holdings in shares of Celldex Therapeutics by 13.5% during the first quarter. California State Teachers Retirement System now owns 58,403 shares of the biopharmaceutical company’s stock valued at $2,451,000 after purchasing an additional 6,929 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Celldex Therapeutics during the first quarter valued at approximately $470,000. Finally, Public Employees Retirement Association of Colorado purchased a new position in Celldex Therapeutics in the 1st quarter worth approximately $327,000.
Celldex Therapeutics Price Performance
NASDAQ CLDX opened at $34.91 on Tuesday. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The business’s 50-day moving average is $37.66 and its 200 day moving average is $39.04.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. As a group, research analysts predict that Celldex Therapeutics will post -2.32 EPS for the current fiscal year.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Recommended Stories
- Five stocks we like better than Celldex Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- CAVA’s Per-Restaurant Stock Value Outshines Chipotle’s
- ESG Stocks, What Investors Should Know
- The Most Shorted Stocks in June: Hold, Short, or Squeeze?
- Best Stocks Under $10.00
- Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.